Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 2/20 | 0.52 |
| ▸ | CALML3 | P27482 | 7/20 | 0.50 |
| ▸ | MAOB | P27338 | 4/20 | 0.44 |
| ▸ | MAOA | P21397 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | SDHA | P31040 | 1/20 | 0.44 |
| ▸ | BPTF | Q12830 | 1/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5917588 | 1.00 | F10 (0.52) | F10CALML3MAOBMAOALMNA | |
| SCHEMBL1036374 | 1.00 | F10 (0.52) | F10CALML3MAOBMAOALMNA | |
| SCHEMBL16701334 | 0.88 | BPTF (0.57) | F10CALML3MAOBMAOALMNA | |
| SCHEMBL16701336 | 0.88 | BPTF (0.57) | F10CALML3MAOBMAOALMNA | |
| SCHEMBL1035579 | 0.87 | CALML3 (0.65) | CALML3MAOBMAOALMNAPTGS1 | |
| SCHEMBL1557322 | 0.87 | CALML3 (0.65) | CALML3MAOBMAOALMNAPTGS1 | |
| SCHEMBL10196158 | 0.87 | CALML3 (0.50) | CALML3MAOBMAOALMNAPTGS1 | |
| SCHEMBL12157633 | 0.86 | F10 (0.57) | F10CALML3MAOBMAOALMNA | |
| SCHEMBL592028 | 0.85 | F10 (0.53) | F10CALML3MAOBMAOALMNA | |
| SCHEMBL592027 | 0.85 | F10 (0.53) | F10CALML3MAOBMAOALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3442526-A1 | TOPICAL FORMULATIONS OF BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | Melinta Subsidiary Corp. (US) | 2019-02-20 | — | — | EP | disclosed |
| WO-2017200979-A1 | TOPICAL FORMULATIONS OF BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | MELINTA THERAPEUTICS, INC. (US) | 2017-11-23 | — | — | WO | disclosed |
| EP-3217974-A1 | METHOD FOR TREATING, PREVENTING, OR REDUCING THE RISK OF SKIN INFECTION | Melinta Therapeutics, Inc. (US) | 2017-09-20 | — | — | EP | disclosed |
| US-9550783-B2 | Biaryl heterocyclic compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9422274-B2 | Oxazolidinone derivatives and composition for preventing or treating hepatitis C containing the same | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2016-08-23 | — | — | US | disclosed |
| WO-2016077818-A1 | METHOD FOR TREATING, PREVENTING, OR REDUCING THE RISK OF SKIN INFECTION | MELINTA THERAPEUTICS, INC. (US) | 2016-05-19 | — | — | WO | disclosed |
| US-20150148386-A1 | Oxazolidinone derivatives and composition for preventing or treating Hepatitis C containing the same | POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) | 2015-05-28 | — | — | US | disclosed |
| US-20150072970-A1 | BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | MELINTA THERAPEUTICS, INC. (US) | 2015-03-12 | — | — | US | disclosed |
| EP-1660465-B1 | PROCESS FOR THE SYNTHESIS OF BIARYL OXAZOLIDINONES | MELINTA THERAPEUTICS INC (US) | 2014-12-17 | — | — | EP | disclosed |
| US-8895741-B2 | Process for the synthesis of biaryl oxazolidinones | MELINTA THERAPEUTICS, INC. (US) | 2014-11-25 | — | — | US | disclosed |
| WO-2006133397-A2 | PROCESS FOR THE SYNTHESIS OF TRIAZOLES | RIB-X PHARMACEUTICALS, INC. (US) | 2006-12-14 | — | — | WO | disclosed |
| US-7148219-B2 | Biaryl heterocyclic compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. (US) | 2006-12-12 | — | — | US | disclosed |
| US-20060264426-A1 | Biaryl heterocyclic compounds and methods of making and using the same | MELINTA SUBSIDIARY CORP. | 2006-11-23 | — | — | US | disclosed |
| EP-1660465-A2 | PROCESS FOR THE SYNTHESIS OF BIARYL OXAZOLIDINONES | Rib-X Pharmaceuticals, Inc. (US) | 2006-05-31 | — | — | EP | disclosed |
| EP-1656370-A2 | BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | Rib-X Pharmaceuticals, Inc. (US) | 2006-05-17 | — | — | EP | disclosed |
| US-6969726-B2 | Biaryl heterocyclic compounds and methods of making and using the same | MELINTA SUBSIDIARY CORP. | 2005-11-29 | — | — | US | disclosed |
| US-20050203147-A1 | Biaryl heterocyclic compounds and methods of making and using the same | MELINTA SUBSIDIARY CORP. | 2005-09-15 | — | — | US | disclosed |
| WO-2005019211-A2 | BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20050043317-A1 | Biaryl heterocyclic compounds and methods of making and using the same | MELINTA SUBSIDIARY CORP. | 2005-02-24 | — | — | US | disclosed |
| WO-2005012271-A2 | PROCESS FOR THE SYNTHESIS OF BIARYL OXAZOLIDINONES | RIB-X PHARMACEUTICALS, INC. (US) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264426-A1 | Biaryl heterocyclic compounds and methods of making and using the same | PCNA, AADAC, MIF | F10 4285/4885CALML3 3842/4885MAOB 994/4885 |
| US-20150072970-A1 | BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PCNA, AADAC, MIF | F10 4285/4885CALML3 3842/4885MAOB 994/4885 |
| US-20050043317-A1 | Biaryl heterocyclic compounds and methods of making and using the same | PCNA, AADAC, MIF | F10 4285/4885CALML3 3842/4885MAOB 994/4885 |
| US-20050203147-A1 | Biaryl heterocyclic compounds and methods of making and using the same | PCNA, AADAC, MIF | F10 4285/4885CALML3 3842/4885MAOB 994/4885 |
| US-20150148386-A1 | Oxazolidinone derivatives and composition for preventing or treating Hepatitis C containing the same | CYP7A1, CYP7B1, CYP3A7 | F10 1979/4885CALML3 4426/4885MAOB 1597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.